Liquor Impacting Brain Activity (Credit-Freepik)
Many of us believe that we are great drinkers and that alcohol does not affect us as much. People who are able to drink without showing any sign of inebriation are known as social drinkers. In short, they are not addicted to alcohol but will not turn down the opportunity to have a good time! While it may seem like it doesn’t affect you, new studies suggest that it is just an illusion, even if you have high tolerance, alcohol affects your cognitive and motor functions more than you think.
The study reveals the below implications and techniques:
Think of it as the foundation for your brain's performance. When brain conductivity is high, information flows smoothly, and that helps your brain in rapid processing and response. On the other hand, low conductivity can hinder cognitive function, leading to slower thinking, impaired memory, and difficulties with coordination.
A study conducted at the Neuroscience Research Australia (NeuRA) and UNSW Science unveiled a startling connection between alcohol consumption and brain conductivity.
While many people brush off the effects of alcohol as temporary changes in behaviour, the reality is much more complex. Beyond the obvious impacts on coordination and judgment, alcohol significantly alters brain function. Alcohol dramatically slowed down brain activity, especially in areas responsible for decision-making, planning, and physical coordination. This decline was so significant that it resembled the brain changes seen in normal ageing. This means even one drink could temporarily accelerate the ageing process of your brain.
The implications of this research are far-reaching. It provides compelling evidence that alcohol consumption has a direct and measurable impact on brain function. The discovery that alcohol can significantly reduce brain conductivity opens new avenues for understanding the neurocognitive effects of alcohol abuse and dependence. While you may not feel like alcohol is affecting you and you have a high tolerance, it most definitely changes and affects your decision-making abilities and impulse control.
Furthermore, the MRI technique employed in the study could be a valuable tool for assessing the impact of other substances on the brain and for developing interventions to mitigate alcohol-related brain damage.
Credit: AI
A blood pressure medicine manufactured in India has been recalled in the US for the second time in three months after a few batches failed a test designed to ensure that the drug dissolves properly in the body.
The medicine is chlorthalidone 25 mg, a commonly used diuretic, or 'water pill', manufactured by Inventia Healthcare Limited in India. The latest recall involves more than 13,500 bottles, while the earlier recall included 11,460 bottles. Both recalls have been classified by the US Food and Drug Administration (FDA) as Class II recalls.
The US Food and Drug Administration recalled chlorthalidone due to “failed dissolution specifications.” It means that when the tablet is swallowed, its active ingredient needs to dissolve at the right rate so the body can absorb the medicine.
If a tablet does not dissolve properly in the body, less of the active ingredient may become available for absorption, making the medicine less effective that it should be.
For someone taking chlorthalidone to control high blood pressure, inadequate drug absorption could mean that blood pressure is not controlled as effectively as intended. The FDA has not reported contamination or a toxic ingredient as the reason for this particular recall.
Also read: Chlorthalidone Recall: FDA Flags Second India-Made Blood Pressure Drug
The first recall was made by Inventia Healthcare on June 5, 2026, involving 11,460 bottles. A second, separate recall was initiated on September 3, involving another 13,567 bottles. The FDA classified this second recall as Class II on September 17. Together, the two recalls affect more than 25,000 bottles of the medication.
The second recall has raised eyebrows as both issues were linked to the same type of manufacturing quality problem, which is failure to meet dissolution specifications.
The earlier recall involved batches RISA24001 and RISB24002. The latest recall involves 25 mg chlorthalidone tablets. Patients must check their medicine packaging for:
Also read: Thyroid Medicine Recall Gets US FDA’s Highest Risk Rating: What To Know
Chlorthalidone is a diuretic used to treat high blood pressure. It works mainly by helping the kidneys remove excess sodium and water from the body. This reduces the amount of fluid circulating through the blood vessels and helps lower blood pressure.
Keeping blood pressure under control is essential as untreated hypertension increases the risk of heart attack, stroke, heart failure and kidney disease.
A Class II recall does not mean the medicine will cause serious harm in everyone who takes it. The FDA defines Class II recalls in which the affected product could cause temporary or medically reversible adverse health consequences, or where the probability of serious harm is remote.
In this case, the concern is primarily that the affected tablets may not work as intended because of inadequate dissolution.
Patients should not stop the medication abruptly without speaking to a doctor or pharmacist. The FDA advises that people generally should not stop a recalled medicine without medical guidance, as suddenly stopping treatment for high blood pressure could be risky.
If you take chlorthalidone, check the batch number on your bottle and contact your pharmacist or healthcare provider if it matches one of the recalled ones.
Credit: iStock
Low-dose CT (LDCT) screening of people at high risk based on age and smoking history can reduce lung cancer deaths and advanced-stage disease, according to an International Agency for Research on Cancer (IARC) working group.
Speaking to HealthandMe, Dr Abhishek Shankar of AIIMS New Delhi, the only Indian author among the 23 experts from 17 countries involved in the IARC review, said India needs to generate its own screening evidence.
The review was published in The New England Journal of Medicine as part of IARC WHO Handbook 21.
Dr Shankar, a lung cancer specialist, said India needs to generate its own screening evidence while ensuring high-risk people have access to screening and follow-up care.
“India should not wait for a perfect screening model and there is a need to generate Indian evidence while ensuring that those at highest risk have access to lung cancer screening and care pathways for screen positive cases,” he said.
Dr Shankar is leading the Indian Lung Screening Trial (ILST), which is assessing risk-based lung cancer screening across 10 centers in India.
Also read: Never Smoked, Still Got Lung Cancer? Rare Gene Mutation Linked To Over 60x Risk
The evidence mainly covers people aged 50 to 80 with a substantial smoking history, typically 20–30 pack-years or more. Studies involving former smokers generally included those who had quit within the previous 10–15 years.
In India, people aged 50 to 80 who have smoked at least 20 pack-years and are current smokers or quit within the past 15 years can contact ILST about screening under the trial.
“High-risk smokers should be encouraged to participate in organized screening rather than opportunistic CT scanning, with appropriate nodule management, follow-up and smoking-cessation support,” Dr Shankar said.
Read More: World Lung Day: Dry Cough, Breathlessness May Not Always Be Asthma — Could It Be ILD?
In the US National Lung Screening Trial, LDCT was linked to a 16% lower relative risk of lung cancer death at seven years compared with chest X-rays. The European NELSON trial also found lower lung cancer mortality among men screened with LDCT at 10 years.
IARC classified LDCT as Group A, indicating established evidence that it reduces lung cancer mortality and stage III or IV disease. Chest X-rays, with or without sputum examination, were classified as Group C, as a mortality benefit could not be established.
LDCT is not meant for everyone. Across studies, false-positive rates ranged from 1% to 42%. Among those with false-positive results, 5% to 32% underwent an invasive procedure, with complications reported in 10% to 22% of those procedures.
The review also estimated that 3% to 26% of lung cancers detected in randomized trials could represent over-diagnosis.
The IARC group stressed that screening requires more than CT scans, including risk assessment, nodule management, follow-up, smoking-cessation support and adequate healthcare capacity.
“India has an opportunity to build an equitable, affordable, locally relevant lung cancer screening pathway and ILST can provide the evidence needed to guide that future,” Dr Shankar said.
Credit: AI
Doctors may soon be able to determine a brain tumour’s type right during the surgery. Doctors remove a tissue sample during surgery to analyse the tumour. Patients undergoing surgery for brain tumour may not have to wait days or weeks to find out.
A new rapid genetic test being tested by the NHS in England promises to shorten the wait time drastically. The technology can find the precise type of brain tumour within about two hours, while the patient is still on the operating table.
Developed by researchers at the University of Nottingham and Nottingham University Hospitals NHS Trust, the test analyses the genetic code of a tumour sample rather than relying only on traditional microscopic examination.
Brain tumours are not connected to one single disease. There are more than 100 types, ranging from relatively slow-growing tumours to highly aggressive cancers. Knowing the exact type and characteristics of a tumour is important because treatment courses can differ significantly.
Traditionally, doctors take a sample during surgery and send it to a pathology laboratory. The tissue sample is then examined under a microscope. Finding out the tumour type usually takes weeks.
According to an NHS centre, the current average time for a brain tumour diagnosis can be around 26 days, while other reports have estimated up to almost eight weeks in some cases. In case of aggressive tumours, waiting period can be particularly difficult and longer.
The rapid genomic test works by analysing a small piece of the tumour which is taken during the surgery and sent to the laboratory, where its DNA is analysed using a shoebox-sized sequencing machine developed by Oxford Nanopore.
Inside the machine, DNA molecules pass through tiny pores. As they move through, the system reads their genetic information and uses the resulting genomic pattern to identify the tumour type.
Marking a significant jump in speed and time taken, the test can help doctors can receive detailed diagnosis during the operation itself instead of weeks.
Also read: Radiotherapy Cuts Risk Of Atypical Meningioma Recurrence By Nearly Half: Lancet Study
Not only this test reduces weeks, sometimes months of anxiety, it can also help surgeons make immediate decisions about how much tumour tissue to remove while protecting healthy brain tissue.
Some tumour types require different surgical approaches, and having molecular information immediately could help the surgeon take quick decisions.
A rapid diagnosis can also help patients to begin the appropriate treatment sooner and gain earlier access to clinical trials designed for specific tumour types.
The NHS is piloting the technology to determine how well rapid genomic testing works in routine clinical practice. The initial rollout covers five specialist centres, including Nottingham University Hospitals, University Hospitals Birmingham, Great Ormond Street Hospital, King's College Hospital and Newcastle Hospitals. More centres are expected to be added soon.
The rapid testing is therefore intended to complement the entire diagnostic process rather than make traditional pathology obsolete. If the NHS pilot is successful, rapid genomic testing could eventually make that information available much earlier to brain tumour patients across England.
© $2026 Times Horizon Private Limited